One of the fastest-growing new categories in GLP-1 litigation. Thousands of patients who took Ozempic and Wegovy developed serious gallbladder disease including gallstones and required emergency surgical removal. FDA adverse event reports confirm thousands of gallbladder-related complaints linked to semaglutide.
Warning: If you required emergency gallbladder removal or were diagnosed with gallbladder disease after taking any GLP-1 medication you may have a valid legal claim. This is an emerging category — law firms are actively seeking plaintiffs right now. Acting early positions you best.
The gallbladder stores and concentrates bile — the digestive fluid used to break down dietary fats. Normally the gallbladder contracts and releases bile when you eat a meal. This regular contraction keeps bile flowing and prevents it from becoming overly concentrated. GLP-1 medications profoundly affect digestion by slowing gastric emptying which indirectly reduces the signals that trigger gallbladder contraction. When the gallbladder contracts less frequently bile sits stagnant. Stagnant bile becomes highly concentrated. Concentrated bile forms cholesterol crystals that eventually become gallstones.
A 2022 large-scale study found that GLP-1 medication users had a significantly higher rate of gallbladder events compared to placebo groups. The FDA adverse event reporting system has received thousands of gallbladder-related complaints specifically linked to semaglutide. Many plaintiffs now filing lawsuits had no prior gallbladder history before beginning Ozempic or Wegovy.
Unlike some GLP-1 injury categories where harm is functional gallbladder removal is a permanent irreversible surgical procedure. A cholecystectomy removes an organ that cannot be replaced or regenerated. While most people can live without a gallbladder the removal creates permanent changes to how bile is delivered to the digestive tract. Many patients experience ongoing digestive symptoms including chronic diarrhea difficulty digesting fatty foods and gastrointestinal discomfort that persists permanently after surgery. The permanence of this harm is central to the legal argument that manufacturers had a duty to warn patients before they began treatment.
Gallbladder injury claims are among the newest categories formally added to the GLP-1 mass tort. There is significantly less competition from other lead gen operations targeting gallbladder-specific plaintiffs compared to the more established gastroparesis and vision loss categories. Patients with gallbladder claims who come forward now are among the earliest cohort in this emerging litigation — and early plaintiffs are consistently better positioned in settlement outcomes. Being an early plaintiff also increases the likelihood of being selected for bellwether trial selection which carries its own strategic advantages.
90 seconds. No cost. No obligation. A specialist contacts you within 24 hours.